2013 Press Releases
This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.
 |
|
| Date | Title | | 12/12/13 | Novan Selected to Present at Inaugural Dermatology Summit| Durham, NC (December 12, 2013) – Novan Therapeutics announced today that the Company has been selected to present at the inaugural Dermatology Summit in San Francisco on January 12, 2014. The Dermatology Summit precedes the JP Morgan Healthcare Conference and brings together leading dermatology companies, financial institutions, and promising technologies to advance innovation in dermatology. Dr. Nathan Stasko, Novan’s President, is scheduled to speak during the Entrepreneurial... |
| | 08/26/13 | Novan Awarded $7.8 Million Contract by BARDA to Develop a Medical Countermeasure for Thermal Burns| Durham, NC (August 26, 2013) – Novan Therapeutics announced today that the U.S. Department of Health and Human Services has entered into a contract with Novan to advance the development of a nitric oxide-based therapy as a topical treatment for thermal burns. The Biomedical Advanced Research and Development Authority (BARDA), an agency within the Office of the Assistant Secretary for Preparedness and Response, awarded this contract. It is widely believed a mass casualty event caused by natural o... |
| | 05/30/13 | Novan Announces Promising Results of SB204 Clinical Study| Phase 2 Clinical Results Expected Early 2014DURHAM, N.C. – Novan Therapeutics, today announced results from a recent clinical trial demonstrating that nitric oxide releasing drug candidate SB204 reduces colonization of the acne causing bacteria Propionibacterium acnes (P. acnes) in the skin of healthy volunteers. This study in combination with Novan's earlier findings regarding sebum production, suggests the formulation may be capable of targeting multiple factors in acne.The Phase 1, thirty-sub... |
| | 03/06/13 | Novan Raises $11M; Acne Drug Heads for Clinical Trial| DURHAM, N.C. — Novan Therapeutics has closed on $11 million in financing as the company heads into clinical trials studying a potential new acne treatment.The Durham company disclosed the new financing in an amended securities filing. The offering follows a $5.1 million round raised last April, in which the company said at the time that the financing could be expanded to $11 million. A total of 50 investors participated in the offering, according to the latest filing.Novan released laboratory an... |
| | 02/28/13 | Novan’s SB204 Could Be First Topical Sebum Inhibitor| Results Drive Development of Novel Acne TreatmentDURHAM, N.C. – Novan Therapeutics, a clinical-stage drug development company, today announced in vitro and animal testing data indicating that the company’s drug candidate, SB204, could lead to a topical treatment to reduce oil production in the skin. SB204 is being developed as a new therapy for acne which is the most common skin disease in the United States, affecting more than 50 million people. None of the current topical products approve... |
|
|
